Prestige Biopharma Limited sell "Tuznue™ (Trastuzumab biosimilar)"

Tuznue is a biosimilar to Herceptin (trastuzumab), created to give patients a more affordable treatment option while matching the original branded drug's efficacy and safety profile. It is indicated for HER2-positive metastatic breast cancer, HER2-positive early breast cancer, and HER2-positive metastatic gastric cancer, and holds Marketing Authorisation from the European Commission.